Provided by Tiger Trade Technology Pte. Ltd.

Invesco Dorsey Wright Healthcare Momentum ETF

61.45
+0.52160.86%
Post-market: 61.450.00000.00%16:10 EDT
Volume:192.56K
Turnover:11.76M
Market Cap:271.61M
PE:20.10
High:62.12
Open:61.37
Low:60.40
Close:60.93
52wk High:64.10
52wk Low:39.36
Shares:4.42M
Float Shares:4.42M
Volume Ratio:6.46
T/O Rate:4.36%
Dividend:1.53
Dividend Rate:2.48%
EPS(TTM):3.06
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Revolution Medicines' Rasonque Label Expands Commercial Opportunity, Oppenheimer Says

MT Newswires Live
·
Aug 28

Street View: Revolution's Pancreatic Cancer Drug Nod Sparks a 'transformative' Era

Reuters
·
Aug 27

Analysts Offer Insights on Healthcare Companies: Revolution Medicines (RVMD) and Immuneering (IMRX)

TIPRANKS
·
Aug 27

Recombinant Collagen Leader Faces Growth Challenges After Weak Interim Results

Deep News
·
Aug 27

Revolution Medicines, Inc. : Oppenheimer Raises Target Price to $260 from $230

THOMSON REUTERS
·
Aug 27

Brightspring Health Services Inc Stock (BTSG) Closed Up by 7.20% on Aug 26: Key Drivers Unveiled

TradingKey
·
Aug 27

Revolution Medicines Prices Metastatic Pancreatic Cancer Drug Rasonque at $39,800 a Month

MT Newswires Live
·
Aug 27

Revolution Medicines to Charge $39,800 a Month for Pancreatic Cancer Drug, Bloomberg Reports

MT Newswires Live
·
Aug 27

Revolution Medicines - Rasonque is NOW Commercially Available in the U.S. at a Wholesale Acquisition Cost of $39,800 for a 30-Day Supply - Conf Call

THOMSON REUTERS
·
Aug 27

Revolution Medicines Posts Investor Presentation on Rasonque FDA Approval

Reuters
·
Aug 27

Revolution Medicines prices Rasonque at $39,800 for 30-day supply

TIPRANKS
·
Aug 27

Revolution Medicines announces FDA approval of Rasonque in adults

TIPRANKS
·
Aug 27

Revolution Medicines, - Rasonque 300 Mg Once-Daily Oral Tablets NOW Available in the U.S.

THOMSON REUTERS
·
Aug 27

U.S. FDA Approves Revolution Medicines’ Rasonque™ (Daraxonrasib), the First Broad Ras-Targeted Medicine in Metastatic Pancreatic Cancer

THOMSON REUTERS
·
Aug 27

U.S. FDA Approves Revolution Medicines’ RASONQUE™ (daraxonrasib), the First Broad RAS-Targeted Medicine in Metastatic Pancreatic Cancer

GlobeNewswire
·
Aug 27

Boston Scientific Hit by Cyberattack, Shares Slide on Delivery Disruption

Deep News
·
Aug 26

FDA Approves Drug for Pancreatic Cancer in Incredible Moment for Deadly Disease

Dow Jones
·
Aug 26

Roivant Says JAMA Dermatology Publishes Phase 3 VALOR Data Showing Brepocitinib Improves Dermatomyositis Skin Outcomes

Reuters
·
Aug 26

Jama Dermatology Publishes Skin-Specific Outcomes from Phase 3 Valor Trial of Brepocitinib in Dermatomyositis

THOMSON REUTERS
·
Aug 26

US FDA Approves Revolution Medicines' Pancreatic Cancer Drug

Reuters
·
Aug 26